The Pulse Check

Escaping the Billing Graveyard: The Pacific Edge Story (ASX: PEB)

May 22, 2026

•

9 min read

Escaping the Billing Graveyard: The Pacific Edge Story (ASX: PEB)

Jason Segal

The Pulse Check

Why Change Management Matters More Than AI in Healthcare

May 21, 2026

•

5 min read

Why Change Management Matters More Than AI in Healthcare

Jason Segal

The Pulse Check

Vital Signs: Live from Digital Health Festival

May 20, 2026

•

2 min read

Vital Signs: Live from Digital Health Festival

Jason Segal

The Pulse Check

May 19, 2026

•

6 min read

The Anatomy of a Short Squeeze

Jason Segal

The Pulse Check

Bet on the Hare, Get the Tortoise: Clinuvel’s Story (ASX: CUV)

May 18, 2026

•

11 min read

Bet on the Hare, Get the Tortoise: Clinuvel’s Story (ASX: CUV)

Jason Segal

The Pulse Check

May 15, 2026

•

2 min read

Don’t cook the float

Jason Segal

The Pulse Check

Innovation Decimation: Budget to Break Biotech

May 14, 2026

•

2 min read

Innovation Decimation: Budget to Break Biotech

Jason Segal

Acrux (ASX: ACR)

The "Kate Bush" Trade: Acrux's (ASX: ACR) Story

May 13, 2026

•

7 min read

The "Kate Bush" Trade: Acrux's (ASX: ACR) Story

Jason Segal

The Pulse Check

May 11, 2026

•

4 min read

Not Your Typical Biotech Shed

Jason Segal

The Pulse Check

May 8, 2026

•

3 min read

The Slow Death of Risk Capital

Jason Segal

Emyria (ASX: EMD)

Spray and Pray: How J&J grew a US$2.3b drug from a three-year bad trip

May 7, 2026

•

6 min read

Spray and Pray: How J&J grew a US$2.3b drug from a three-year bad trip

Jason Segal

The Pulse Check

Research & Dilution: The Truth about R&D

May 6, 2026

•

8 min read

Research & Dilution: The Truth about R&D

Jason Segal

The Pulse Check

May 5, 2026

•

3 min read

100 Articles In... What have I learned?

Jason Segal

InteliCare (ASX: ICR)

Well... that aged poorly: Aged Care Industry Spotlight

May 4, 2026

•

9 min read

Well... that aged poorly: Aged Care Industry Spotlight

Jason Segal

The Pulse Check

Can "soon" move the market? Deals Whispered, not Signed

May 1, 2026

•

5 min read

Can "soon" move the market? Deals Whispered, not Signed

Jason Segal

The Pulse Check

Sailing the 4Cs: Highlights from Reporting Season

Apr 30, 2026

•

3 min read

Sailing the 4Cs: Highlights from Reporting Season

Jason Segal

Dimerix (ASX: DXB)

Apr 29, 2026

•

13 min read

'Timing' or 'Time in' the Market? The Dimerix (ASX: DXB) Story

Jason Segal

The Pulse Check

Apr 28, 2026

•

2 min read

Compare the Care

Jason Segal

The Pulse Check

Apr 27, 2026

•

7 min read

Life in the FDA Fast Lane

Jason Segal

The Pulse Check

Time to Leverage Up: The Nexalis (ASX: NX1) Story

Apr 24, 2026

•

7 min read

Time to Leverage Up: The Nexalis (ASX: NX1) Story

Jason Segal

The Pulse Check

Blue Chipped: What happened to Cochlear (ASX: COH)?

Apr 23, 2026

•

4 min read

Blue Chipped: What happened to Cochlear (ASX: COH)?

Jason Segal

The Pulse Check

CAR-T Blanche: Big Pharma Writes Another Billion-Dollar Cheque

Apr 22, 2026

•

4 min read

CAR-T Blanche: Big Pharma Writes Another Billion-Dollar Cheque

Jason Segal

Emyria (ASX: EMD)

Apr 21, 2026

•

7 min read

The Economics of Psychedelic Therapy

Jason Segal

The Pulse Check

Trump Greenlights Psychedelics in the US for PTSD

Apr 20, 2026

•

2 min read

Trump Greenlights Psychedelics in the US for PTSD

Jason Segal

Emyria (ASX: EMD)

Apr 20, 2026

•

11 min read

My Second Armchair Pick: Emyria (ASX: EMD)

Jason Segal

The Pulse Check

Escaping the Billing Graveyard: The Pacific Edge Story (ASX: PEB)

Why Change Management Matters More Than AI in Healthcare

Vital Signs: Live from Digital Health Festival

The Anatomy of a Short Squeeze

Bet on the Hare, Get the Tortoise: Clinuvel’s Story (ASX: CUV)

Don’t cook the float

Innovation Decimation: Budget to Break Biotech

The "Kate Bush" Trade: Acrux's (ASX: ACR) Story

Not Your Typical Biotech Shed

The Slow Death of Risk Capital

Spray and Pray: How J&J grew a US$2.3b drug from a three-year bad trip

Research & Dilution: The Truth about R&D

100 Articles In... What have I learned?

Well... that aged poorly: Aged Care Industry Spotlight

Can "soon" move the market? Deals Whispered, not Signed

Sailing the 4Cs: Highlights from Reporting Season

'Timing' or 'Time in' the Market? The Dimerix (ASX: DXB) Story

Compare the Care

Life in the FDA Fast Lane

Time to Leverage Up: The Nexalis (ASX: NX1) Story

Blue Chipped: What happened to Cochlear (ASX: COH)?

CAR-T Blanche: Big Pharma Writes Another Billion-Dollar Cheque

The Economics of Psychedelic Therapy

Trump Greenlights Psychedelics in the US for PTSD

My Second Armchair Pick: Emyria (ASX: EMD)

The Armchair Analyst